Diabetes. 2012;61(5):1243-1249. Our studies underline several important parameters to take into consideration when designing studies to look for histological diagnosis of rare findings such as ...

No. 2 / 2025 Zealand Pharma Announces Financial Results for the Full Year 2024 A transformational year with significant ...

No. 2 / 2025 Correction includes 2024 Annual Report attached in iXBRL format. Zealand Pharma Announces Financial Results for ...

The biosimilars reach the US market as the US insulin space has seen seismic changes in the last few years, with a clamour of ...

Altimmune's existence depends almost entirely on the outcome of the Phase 2 trial for pemvidutide in MASH. Learn why ALT ...

Q4 2024 Earnings Call Transcript February 13, 2025 Vanda Pharmaceuticals Inc. beats earnings expectations. Reported EPS is ...

Vapourtec’s R-Series flow chemistry system, equipped with a UV-150 photochemical reactor, has been cited in research by scientists* at Novo Nordisk in the C-terminal α-amination of peptides and ...

HS-10535 is a glucagon-like peptide (GLP)-1 analog under development as an oral medication, similar to Novo Nordisk's Wigov. Merck is also collaborating with another Chinese corporation to license an ...

Q4 2024 total revenues of $53.2 million, +17% compared to Q4 2023 Q4 2024 Fanapt® net product sales of $26.6 million, +18% compared to Q4 2023 Full year 2024 total ...

We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to take a look at where Akero Therapeutics, Inc. (NASDAQ:AKRO) stands against ...

Semaglutide is a GLP-1 agonist that works by reducing appetite, delaying gastric emptying, increasing insulin release, and lowering the amount of glucagon released. Semaglutide is a glucagon-like ...

Scientists at Novo Nordisk have demonstrated a photochemically enabled strategy for the functionalisation of peptides and ...